NEXLETOL
Peakbempedoic acid
NDAORALTABLET
Approved
Feb 2020
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
14
Mechanism of Action
Adenosine Triphosphate-Citrate Lyase Inhibitors
Pharmacologic Class:
Adenosine Triphosphate-Citrate Lyase Inhibitor
Clinical Trials (5)
triPle Oral thERapy With Bempedoic Acid vs uSual Care in Early Lipid Management of Patients With acUte coronAry synDromE
Started Sep 2026
600 enrolled
Acute Coronary SyndromesSecondary PreventionLipids
A Study of Bempedoic Acid/Ezetimibe/High-intensity Statin in Patients Without Cardiovascular Events
Started Jun 2026
103 enrolled
Coronary AtherosclerosisMixed DyslipidemiaHypercholesterolemia
A Study of Bempedoic Acid or Its Single-pill Combination Therapy With Ezetimibe in Patients With Primary Hypercholesterolaemia or Mixed Dyslipidaemia
Started Jan 2026
2,560 enrolled
Primary HypercholesterolaemiaMixed Dyslipidemia
Evaluating Bioequivalence of a Fixed Dose Combination Versus Individual Tablets of Bempedoic Acid / Ezetimibe, and Atorvastatin
Started Dec 2025
58 enrolled
Healthy Subjects
A Study Evaluating Bioequivalence of a Fixed Dose Combination Versus Individual Tablets of Bempedoic Acid, Ezetimibe, and Atorvastatin
Started Oct 2025
58 enrolled
Healthy Subjects
Loss of Exclusivity
LOE Date
Jun 19, 2040
173 months away
Patent Expiry
Jun 19, 2040
Exclusivity Expiry
Mar 22, 2027